EUVIMEDEUVIMED entdecken
Crossref

Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin

Jianglan Long, Qiushi Fang, Zhe Shi, Zenghui Miao, Dan Yan iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Jianglan Long und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Biomarkers. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research, the Youth Beijing Scholar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To explore biomarkers that can predict the response of type 2 diabetes (T2D) patients to metformin at an early stage to provide better treatment for T2D.

Methods

T2D patients with (responders) or without response (non‐responders) to metformin were recruited, and their serum samples were used for metabolomic analysis to identify candidate biomarkers. Moreover, the efficacy of metformin was verified by insulin‐resistant mice, and the candidate biomarkers were verified to determine the biomarkers. Five different machine learning methods were used to construct the integrated biomarker profiling (IBP) with the biomarkers to predict the response of T2D patients to metformin.

Results

A total of 73 responders and 63 non‐responders were recruited, and 88 differential metabolites were identified in the serum samples. After being verified in mice, 19 of the 88 were considered as candidate biomarkers. Next, after metformin regulation, nine candidate biomarkers were confirmed as the biomarkers. After comparing five machine learning models, the nine biomarkers were constructed into the IBP for predicting the response of T2D patients to metformin based on the Naïve Bayes classifier, which was verified with an accuracy of 89.70%.

Conclusions

The IBP composed of nine biomarkers can be used to predict the response of T2D patients to metformin, enabling clinicians to start a combined medication strategy as soon as possible if T2D patients do not respond to metformin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2Hypoglycemic AgentsBiomarkersMachine LearningHumansAnimalsMiceMaleFemaleMiddle AgedMetabolomicsTreatment OutcomeMice, Inbred C57BLInsulin ResistanceAged

Stichwörter der Autor:innen

Naïve Bayes classifierintegrated biomarker profilingmachine learningmetformintype 2 diabetes

Substanzen

MetforminHypoglycemic AgentsBiomarkers

Autor:innen und Institutionen

  • Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Dan Yan

Förderung

  • the National Natural Science Foundation of China
  • Capital's Funds for Health Improvement and Research
  • the Youth Beijing Scholar
  • National Natural Science Foundation of China

Zitieren

APA

Long, J., Fang, Q., Shi, Z., Miao, Z., & Yan, D. (2024). Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15689

Vancouver

Long J, Fang Q, Shi Z, Miao Z, Yan D. Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15689

BibTeX
@article{Long2024,
  author = {Long, Jianglan and Fang, Qiushi and Shi, Zhe and Miao, Zenghui and Yan, Dan},
  title = {Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15689}
}
Kostenlos starten →